coparison of the teraputic effect of pioglitazone and ,and metformin on ultra sound scoring and liver enzymez in potients with non alcoholic fatty liver disease

Abstract

Introduction: Non-alcoholic fatty liver disease is a common liver disease that can lead to cirrhosis if left untreated. There is a strong association between this disease and insulin resistance and oxidative stress; therefore, tissue hypersensitivity drugs to insulin and antioxidants can be used to treat this disease. . . . . . . . . Objective: Evaluation of efficacy of pioglitazone and Vitamin E synchronic prescription compared to synchronic prescription of metformin and Vitamin E on ultrasound grid and liver enzymes in patients with non-alcoholic fatty liver. Method: This study is a random clinical trial in which 68 patients were randomly selected and divided into two intervention groups. One group of patients received pioglitazone with Vitamin E and the other group received metformin with Vitamin E for 6 months daily. Study participants ranged in age from 18 to 65 years with confirmed NAFLD based on ultrasound results and clinical trials. Drug-sensitive, pregnant, lactating, and alcohol abusers have been excluded from the study. Results: Concomitant administration of metformin and vitamin E, as well as co-administration of pioglitazone and vitamin E for liver ultrasound grade both significantly reduced the percentage of patients with grade 2 fatty liver and the percentage of patients with grade 2 fatty liver. Conclusion: Synchronic prescription of metformin and Vitamin E is both more effective in reducing fatty liver ultrasound grid and improving liver enzymes than synchronic prescription of pioglitazone and Vitamin E.